Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC

In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!

STATEMENT OF NEED

Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the United States, non"small cell lung cancer (NSCLC) accounts for 81% of all lung cancer diagnoses (Cancer.net, 2023). Therapeutic options, survival rates, and outcomes for NSCLC are dramatically impacted by disease stage. For patients with early-stage disease, radical surgery is the mainstay of treatment; however, patients have a significant risk of relapse following surgery and local treatment. Numerous novel therapeutic approaches, including the use of molecular biomarkers and the development of targeted agents and immune checkpoint inhibitors, are under investigation for early-stage NSCLC, contributing to a growing arsenal of treatment options for this disease (Indini et al, 2020). In this activity, Helena A. Yu, MD, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide expert perspectives on diagnosis, identification of biomarkers, and efficacy and safety data of novel adjuvant therapies to improve survival outcomes for patients with early-stage NSCLC.

TARGET AUDIENCE

Medical oncologists, radiation oncologists, surgical oncologists, pulmonologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with non"small cell lung cancer (NSCLC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

-Identify the correct tumor stage and appropriate management approach for NSCLC based on the latest evidence
-Distinguish biomarkers for early-stage NSCLC that can inform individualized treatment strategies
-Appraise efficacy and safety data of novel adjuvant therapies for patients with NSCLC as elucidated by recent clinical trials
-Apply strategies to prevent and mitigate adverse events associated with novel adjuvant therapies for early-stage NSCLC